CSIMarket
 


Aimmune Therapeutics Inc   (AIMT)
Other Ticker:  
 

Aimmune Therapeutics Inc 's Tangible Leverage Ratio

AIMT's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 0.49%, Tangible Leverage Ratio fell to 0.97, a new company high.

Within Major Pharmaceutical Preparations industry in the second quarter 2020, 304 other companies have achieved lower Tangible Leverage Ratio than Aimmune Therapeutics Inc in the II Quarter 2020. While Tangible Leverage Ratio total ranking has deteriorated compared to the first quarter 2020 from 1525 to 1763 .

Explain Tangible Leverage Ratio?
What is AIMT Market Share?
What are AIMT´s Total Liabilities?


AIMT Tangible Leverage Ratio (Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
Y / Y Tangible Equity Change -12.25 % -8.29 % -65.2 % -38.22 % -28.79 %
Y / Y Total Liabilities Change 115.13 % 132.81 % 115.63 % 104.45 % 108.01 %
Tangible Leverage Ratio MRQ 0.97 0.74 0.84 0.54 0.39
AIMT's Total Ranking # 1763 # 1525 # 642 # 1473 # 690
Seq. Tangible Equity Change -23.48 % 125.95 % -31.87 % -25.51 % -20.03 %
Seq. Total Liabilities Change 0.49 % 97.42 % 6.28 % 2.04 % 8.74 %



Tangible Leverage Ratio second quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 305
Healthcare Sector # 579
Overall Market # 1763


Tangible Leverage Ratio Statistics
High Average Low
0.97 0.24 0.02
(Jun 30 2020)  




Financial Statements
Aimmune Therapeutics Inc 's Tangible Equity $ 180 Millions Visit AIMT's Balance sheet
Aimmune Therapeutics Inc 's Total Liabilities $ 174 Millions Visit AIMT's Balance sheet
Source of AIMT's Sales Visit AIMT's Sales by Geography


Cumulative Aimmune Therapeutics Inc 's Tangible Leverage Ratio

AIMT's Tangible Leverage Ratio for the trailling 12 Months

AIMT Tangible Leverage Ratio

(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
Y / Y Tangible Equity TTM Growth -12.25 % -8.29 % -65.2 % -38.22 % -28.79 %
Y / Y Total Liabilities TTM Growth 115.13 % 132.81 % 115.63 % 104.45 % 108.01 %
Tangible Leverage Ratio TTM 0.77 0.61 0.45 0.3 0.23
Total Ranking TTM # 15 # 906 # 275 # 11 # 11
Seq. Tangible Equity TTM Growth -23.48 % 125.95 % -31.87 % -25.51 % -20.03 %
Seq. Total Liabilities TTM Growth 0.49 % 97.42 % 6.28 % 2.04 % 8.74 %


On the trailing twelve months basis Due to the net new borrowings of 0.49% during the trailing twelve months finishing in the II Quarter 2020, cumulativeTangible Leverage Ratio improved to 0.77, above the Aimmune Therapeutics Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry AIMT recorded the lowest Tangible Leverage Ratio. While Tangible Leverage Ratio total ranking has improved so far to 15, from total ranking in previous 12 month period at 906.

Explain Tangible Leverage Ratio?
What is AIMT Market Share?
What are AIMT´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 0
Within the Market # 15


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.84 0.21 0.03
(Jun 30 2020)   (Jun 30 2016)




Companies with similar Tangible Leverage Ratio in the quarter ending Jun 30 2020, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioJun 30 2020 MRQ Total LiabilitiesJun 30 2020 MRQ Tangible Equity
Cumberland Pharmaceuticals Inc  2.62 $ 48.075  Millions$ 18.378  Millions
Harrow Inc   2.57 $ 33.726  Millions$ 13.104  Millions
Pacira Biosciences inc   2.54 $ 477.963  Millions$ 188.147  Millions
Eterna Therapeutics Inc   2.52 $ 4.859  Millions$ 1.931  Millions
Regulus Therapeutics Inc   2.51 $ 21.198  Millions$ 8.462  Millions
Amicus Therapeutics inc   2.43 $ 340.498  Millions$ 140.156  Millions
Akebia Therapeutics Inc   2.38 $ 374.914  Millions$ 157.723  Millions
Pulmatrix Inc   2.06 $ 21.187  Millions$ 10.308  Millions
Galera Therapeutics Inc   2.00 $ 74.058  Millions$ 37.098  Millions
Lifecore Biomedical Inc   1.98 $ 270.303  Millions$ 136.330  Millions
Dmk Pharmaceuticals Corporation  1.96 $ 16.583  Millions$ 8.459  Millions
Athenex Inc   1.96 $ 156.032  Millions$ 79.735  Millions
Karyopharm Therapeutics Inc   1.91 $ 248.434  Millions$ 129.799  Millions
Alexion Pharmaceuticals Inc   1.85 $ 6,212.400  Millions$ 3,355.900  Millions
Perrigo Company Plc  1.83 $ 5,561.800  Millions$ 3,031.100  Millions
Protokinetix Incorporated  1.83 $ 0.030  Millions$ 0.016  Millions
Strongbridge Biopharma plc  1.80 $ 32.402  Millions$ 18.014  Millions
China Pharma Holdings Inc   1.80 $ 14.767  Millions$ 8.213  Millions
Reata Pharmaceuticals Inc   1.80 $ 416.089  Millions$ 231.627  Millions
Travere Therapeutics Inc   1.80 $ 291.449  Millions$ 162.338  Millions
Opko Health Inc   1.76 $ 735.391  Millions$ 417.619  Millions
Statera Biopharma Inc fka Cytocom Inc   1.76 $ 5.788  Millions$ 3.292  Millions
Apellis Pharmaceuticals Inc   1.74 $ 404.168  Millions$ 232.064  Millions
Sarepta Therapeutics Inc   1.70 $ 1,750.866  Millions$ 1,029.761  Millions
Mei Pharma Inc   1.68 $ 131.510  Millions$ 78.218  Millions
Fortress Biotech Inc   1.68 $ 184.845  Millions$ 110.191  Millions
Morphosys Ag  1.68 $ 1,162.774  Millions$ 694.067  Millions
Aytu Biopharma Inc   1.67 $ 57.821  Millions$ 34.657  Millions
Veru Inc   1.65 $ 23.909  Millions$ 14.469  Millions
Biodelivery Sciences International Inc   1.65 $ 135.303  Millions$ 82.055  Millions

Date modified: 2023-03-24T07:53:52+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com